Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jason Raleigh Nunn Insider Profile
4 Followers
Jason Raleigh Nunn, Director at Hyperion Therapeutics, holds 0.00 shares in Hyperion Therapeutics (Ticker: HPTX), holds ― shares in Regulus (Ticker: RGLS), holds 6.00K shares in Journey Medical Corp (Ticker: DERM).
Jason Raleigh Nunn Hyperion Therapeutics (HPTX)Director
Hyperion Therapeutics (HPTX)
Director
Not Ranked
Jason Raleigh Nunn has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Jason Raleigh Nunn holds in companies
Most Profitable Insider Trade
The most profitable trade made by Jason Raleigh Nunn
Jason Raleigh Nunn's Trading History
Hyperion Therapeutics
May 11, 2015
―
Uninformative Sell
123.60K
―
Regulus
―
Director
―
―
Journey Medical Corp
―
Director
―
$28.08K
Zenas BioPharma, Inc.
Sep 16, 2024
Director
Uninformative Buy
―
$30.60M
Trevena
Dec 10, 2015
Director
Uninformative Buy
―
$7.52K
Trivascular Technologies
―
―
―
$0.00
Dermira
―
―
―
$112.50K
Paratek Pharmaceuticals
―
―
―
$0.00
List of latest transactions for each holding click on a transaction to see Jason Raleigh Nunn's performance on stock
You May Also Like
Jason Raleigh Nunn insider profile FAQ
What is the percentage of profitable transactions made by Jason Raleigh Nunn?
The percentage of profitable transactions made by Jason Raleigh Nunn is ―.
What is the average return per transaction made by Jason Raleigh Nunn?
The average return per transaction made by Jason Raleigh Nunn is ―.
What stocks does Jason Raleigh Nunn hold?
Jason Raleigh Nunn holds: HPTX, RGLS, DERM, ZBIO, TRVN, TRIV, ~DERM, PRTK stocks.
What was Jason Raleigh Nunn’s latest transaction?
Jason Raleigh Nunn latest transaction was an Uninformative Sell of $123.60K.
What was Jason Raleigh Nunn's most profitable transaction?
Jason Raleigh Nunn’s most profitable transaction was an Informative Buy of ZBIO stock on September 16, 2024. The return on the trade was -44.20%.
What is Jason Raleigh Nunn's role in Hyperion Therapeutics?
Jason Raleigh Nunn's role in Hyperion Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.